Sage expects that, based on its current estimates, its current cash, cash equivalents and marketable securities, along with anticipated funding from ongoing collaborations, collaboration revenue from sales of ZURZUVAE, and a potential milestone payment of $75.0M from Biogen for the first commercial sale of ZURZUVAE for the treatment of women with PPD, will support operations into 2026. Additionally, Sage underwent a strategic reorganization and pipeline reprioritization in August 2023. The company expects annualized net savings of approximately $240M, of which 60% is related to R&D. The annualized net savings include $100M related to the workforce reduction.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAGE:
- SAGE Earnings this Week: How Will it Perform?
- Sage receives Orphan Drug Designation for SAGE-718 from FDA
- Sage Therapeutics participates in a conference call with Jefferies
- Sage Therapeutics management to meet with Oppenheimer
- Sage Therapeutics price target lowered to $24 from $25 at BofA
Questions or Comments about the article? Write to editor@tipranks.com